Author:
Kudriavtseva O. M.,Semakova A. P.,Mikshis N. I.,Popova P. Yu.,Kozhevnikov V. A.,Stepanov A. V.,Bugorkova S. A.
Subject
Applied Microbiology and Biotechnology,Biochemistry
Reference21 articles.
1. Semenov, B.F., Zverev, V.V., and Khaitov, R.M., Vaccine prophylaxis in the 21st century: the present and the future, Immunologiya, 2009, vol. 30, no. 6, pp. 324–335.
2. Bode, C., Zhao, G., Steinhagen, F., et al., CpG DNA as a vaccine adjuvant, Expert Rev. Vaccines, 2011, vol. 10, no. 4, pp. 499–511. doi 10.1586/erv.10.174
3. Zhu, Q., Egelston, C., Vivekanandhan, A., et al., Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines, Proc. Natl. Acad. Sci. U. S. A., 2008, vol. 105, no. 42, pp. 16 260–16 265. doi 10.1073/pnas.0805325105
4. Vollmer, J., Weeratna, R., Payette, P., et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities, Eur. J. Immunol., 2004, vol. 34, no. 1, pp. 251–262. doi 10.1002/eji.200324032
5. Gupta, K. and Cooper, C., A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases, Drugs R. D., 2008, vol. 9, no. 3, pp. 137—145.